Contraception in patients with a history of cancer: skin, gastrointestinal, hematological, and endocrine cancers (Part II)

DOI

https://dx.doi.org/10.18565/aig.2022.187

Yakushevskaya O.V., Yureneva S.V., Ashrafyan L.A., Babaeva N.A.
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

As the body grows old, the risk of cancers increases. Aging is one of the most significant risk factors for cancer. The peak (65%) incidence rate of cancers is noticed at the age of 63 years. However, at a younger age of 30–59 years, a third (33%) of all neoplasias is detected in women. Young people are most often diagnosed with hereditary cancer syndromes that result from genetic defects. Early diagnosis and the latest advances in anticancer therapy form the basis for increasing survival and reducing cancer death rate. After the successful completion of therapy for a malignant neoplasm, some patients need effective contraception, because the onset of pregnancy may be associated with a high risk for progression or recurrence of the neoplastic process. To date, there have been no clearly formulated recommendations or protocols for prescribing contraception in patients with a family history of cancer. This paper gives the results of the work of the European Society of Contraception Expert Group that has attempted to identify the most common types of cancers in women who are likely to need this or that contraception methods to be prescribed after their cure. Information on the characteristics of treatment, its impact on fertility, efficiency/risks to health, possible benefits and contraindications to the available contraception methods is analyzed for each type of cancer. The obtained information (of studies and reviews) is summarized in the guidelines for contraception for each type of cancer. Due to a large amount of information, the results are presented in two parts. Part 1 includes the contraception methods used after breast and reproductive organ cancers. Part 2 summarizes results and recommendations regarding contraception in women with a history of skin, gastrointestinal, hematological, and endocrine cancers.
Conclusion. Patients with a family history of cancer should be informed about the level of safety and efficiency of this and that contraception method. Most experts hold to the idea that non-hormonal contraception methods should be a priority. However, emergency contraception is permitted in any case.

cancer

contraception

skin cancer

colorectal cancer

hepatocellular cancer

endocrine cancer

leukemia

lymphoma

melanoma

Full text (in Russian)

Cagnacci A., Ramirez I., Bitzer J., Gompel A. Contraception in cancer survivors – an expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers. Eur. J. Contracept. Rep. Health Care. 2019; 24(4): 299-304.https://dx.doi.org/10.1080/13625187.2019.1604947.
Global Cancer Observatory. 2018. All cancers. Available at: http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancersfact-sheet.pdf Accessed 15 March 2019.
Da Silva F.C., Wernhoff P., Dominguez-Barrera C., Dominguez-Valentin M. Update on hereditary colorectal cancer. Anticancer Res. 2016; 36(9): 4399-405. https://dx.doi.org/10.21873/anticanres.10983.
Syngal S., Brand R.E., Church J.M., Giardiello F.M., Hampel H.L., Burt R.W.;American College of Gastroenterology. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am. J. Gastroenterol. 2015; 110(2): 223-62. https://dx.doi.org/10.1038/ajg.2014.435.
Carethers J.M., Stoffel E.M. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J. Gastroenterol. 2015; 21(31): 9253-61. https://dx.doi.org/10.3748/wjg.v21.i31.9253.
Cercek A., Siegel C.L., Capanu M. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clin. Colorectal Cancer. 2013; 12(3): 163-7.https://dx.doi.org/10.1016/j.clcc.2013.04.007.
Wan J., Gai Y., Li G., Tao Z., Zhang Z. Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer. Clin. Colorectal Cancer. 2015; 14(1): 31-4.https://dx.doi.org/10.1016/j.clcc.2014.09.012.
Cibula D., Gompel A., Mueck A.O., La Vecchia C., Hannaford P.C.,Skouby S.O. et al. Hormonal contraception and risk of cancer. Hum. Reprod. Update. 2010; 16(6): 631-50. https://dx.doi.org/10.1093/humupd/dmq022.
Lu K.H., Loose D.S., Yates M.S., Nogueras-Gonzalez G.M., Munsell M.F.,Chen L.M. et al. Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus Depo-Provera for prevention of endometrial cancer in women with Lynch syndrome. Cancer Prev. Res. (Phila). 2013; 6(8): 774-81. https://dx.doi.org/10.1158/1940-6207.CAPR-13-0020.
Sangiovanni A., Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016; 36(Suppl. 1): 124-9.https://dx.doi.org/10.1111/liv.13028.
Maheshwari S., Sarraj A. Oral contraception and the risk of hepatocellular carcinoma. J. Hepatol. 2007; 47(4): 506-13. https://dx.doi.org/10.1016/j.jhep.2007.03.015.
Teras L.R., DeSantis C.E., Cerhan J.R., Morton L.M., Jemal A., Flowers C.R. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 2016; 66(6): 443-59. https://dx.doi.org/10.3322/caac.21357.
Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391-405.https://dx.doi.org/10.1182/blood-2016-03-643544.
Chen H., Xiao L., Li J. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women (Review). Cochrane Database Syst. Rev. 2019; (3): CD008018. https://dx.doi.org/10.1002/14651858. CD008018.pub3.
Elgindy E., Sibai H., Abdelghani A., Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet. Gynecol. 2015; 126(1): 187-95. https://dx.doi.org/10.1097/AOG.0000000000000905.
Oktay K., Harvey B.E., Partridge A.H., Quinn G.P., Reinecke J., Taylor H.S. et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol. 2018; 36(19): 1994-2001. https://dx.doi.org/10.1200/JCO.2018.78.1914.
Kane E.V., Roman E., Becker N., Bernstein L., Boffetta P., Bracci P.M. Menstrual and reproductive factors, and hormonal сontraception use: аssociations with non-Hodgkin lymphoma in a pooled analysis of Inter Lymph case–control studies. Ann. Oncol. 2012; 23(9): 2362-74. https://dx.doi.org/10.1093/annonc/mds171.
Costas L., Lambert B.H., Birmann B.M., Moysich K.B., De Roos A.J., Hofmann J.N. et al. A pooled analysis of reproductive factors, exogenous hormone use, and risk of multiple myeloma among women in the International Multiple Myeloma Consortium. Cancer Epidemiol. Biomarkers Prev. 2016; 25(1): 217-21. https://dx.doi.org/10.1158/1055-9965.EPI-15-0953.
Roman E., Smith A., Appleton S., Crouch S., Kelly R., Kinsey S. et al. Cancer Epidemiol. 2016; 42: 186-98. https://dx.doi.org/10.1016/j.canep.2016.03.011.
Yaish I., Azem F., Gutfeld O., Silman Z., Serebro M., Sharon O. et al. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a prospective pilot study. Thyroid. 2018; 28(4): 522-7. https://dx.doi.org/10.1089/thy.2017.0442.
Evranos B., Faki S., Polat S.B., Bestepe N., Ersoy R., Cakir B. et al. Effects of radioactive iodine therapy on ovarian reserve: a prospective pilot study. Thyroid. 2018; 28(12): 1702-7. https://dx.doi.org/10.1089/thy.2018.0129.
Braganza M.Z., de Gonzalez A.B., Schonfeld S.J., Wentzensen N., Brenner A.V., Kitahara C.M. Benign breast and gynecologic conditions, reproductive and hormonal factors, and risk of thyroid cancer. Cancer Prev. Res. (Phila). 2014; 7(4): 418-25. https://dx.doi.org/10.1158/1940-6207.CAPR-13-0367.
Xhaard C., Rubino C., Clero E., Maillard S., Ren Y., Borson-Chazot F. et al.Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: a population-based case-control study. Am. J. Epidemiol. 2014; 180(10): 1007-17. https://dx.doi.org/10.1093/aje/kwu220.
Tang B., Lv J., Li Y., Yuan S., Wang Z., He S. Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore). 2015; 94(4): e17.https://dx.doi.org/10.1097/MD.0000000000000177.
Lee E., Horn-Ross P.L., Rull R.P., Neuhausen S.L., Anton-Culver H., Ursin G. et al. Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Am. J. Epidemiol. 2013; 178(9): 1403-13. https://dx.doi.10.1093/aje/kwt154.
Fassnacht M., Dekkers O.M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 2018; 179(4): G1-46. https://dx.doi.org/10.1530/EJE-18-0608.

Received 08.08.2021

Accepted 13.09.2022

Oksana V. Yakushevskaya, PhD, Researcher at the Department of Gynecological Endocrinology, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, aluckyone777@gmail.com. https://orcid.org/0000-0002-7430-1207, 117997, Russia, Moscow, Ac. Oparina str., 4.
Svetlana V. Yureneva, Dr. Med. Sci., Deputy Director in Science, Institute of Oncology and Mammology, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, syureneva@gmail.com https://orcid.org/0000-0003-2864-066X, 117997, Russia, Moscow, Ac. Oparina str., 4.
Levon A., Ashrafyan, Academician of the RAS, Dr. Med. Sci., Professor, Director of the Institute of Oncology and Mammology, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, levaa2004@yahoo.com, https://orcid.org/0000-0002-4194-664Х,
117997, Russia, Moscow, Ac. Oparina str., 4.
Nataliya A. Babaeva, Dr. Med. Sci., Oncologist, Oncological Department of Surgical Methods of Treatment; Leading Researcher, Institute of Oncogynecology and Mammology, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, natbabaeva@yandex.ru,
https://orcid.org/0000-0002-4654-9512, 117997, Russia, Moscow, Ac. Oparina str., 4.

Authors’ contributions: Yakushevskaya O.V. – material collection and processing, writing the text; Yureneva S.V., Ashrafyan L.A., Babaeva N.A. – editing.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The investigation has not been sponsored.
For citation: Yakushevskaya O.V., Yureneva S.V.,
Ashrafyan L.A., Babaeva N.A. Contraception in patients with a history of cancer:
skin, gastrointestinal, hematological, and endocrine cancers (Part II).
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2022; 12: 50-56 (in Russian)
https://dx.doi.org/10.18565/aig.2022.187

Contraception in patients with a history of cancer: skin, gastrointestinal, hematological, and endocrine cancers (Part II)

Yakushevskaya O.V., Yureneva S.V., Ashrafyan L.A., Babaeva N.A.

Keywords

References

About the Authors

Similar Articles